Objective-To determine rates of colonisation with Haemophilus influenzae type b among household contacts 
Introduction
Although epidemics ofinvasive Haemophilus influenzae type b disease are rare, the incidence of the disease among susceptible close contacts of affected children is 500-600 times higher than in other children in the same age group.4 Most secondary cases occur in the week after onset of disease in the index case; the risk is about 2% in contacts aged under 4 1-2% of cases, and rifampicin prophylaxis as recommended is time consuming; costly; and is associated with risk of side effects, possible development of rifampicin resistance by the organism, and, sometimes, failure to prevent disease.9 '°M ost contacts in whom H influenzae type b colonisation and secondary disease have been studied were of patients with meningitis. Among the relatively few contacts of patients with epiglottitis studied, the trend was towards lower rates of colonisation than among those of patients with meningitis," 12 However, the recommendations for prophylaxis do As soon as possible after admission one or both parents were interviewed and asked to answer a questionnaire, which included detailed medical, family, and social histories (to be reported elsewhere). Throat swabs were taken from the patient and house-hold contacts while the patient was in hospital (if possible before rifampicin was given). If necessarv, a research nurse visited the patient's home to collect the specimens. Follow up swabs were collected from the patient and household contacts during a visit to the family's home by the research nurse, about six weeks after the admission (usually at least four weeks after discharge).
Throat swabs were taken with a standard technique. The swab was placed into 1 ml of Levinthal (table II) .
Rifampicin "prophylaxis"- Table III . In the families in which all members received rifampicin only 3% (1/39) of children were colonised at follow up; among siblings who were given rifampicin but either whose parents or the index patient were not 21% (8/39) were colonised at follow up, which was not quite significantly different from that in children not treated with rifampicin (36%, 39/108; p=0053).
Discussion
We assumed that pharyngeal colonisation with H influenzae type b precedes invasive disease. The isolation rate of only 70% from patients whose throat swabs were taken on the day of admission probably reflects the fact that a single swab is relatively insensitive for detecting colonisation, especially if cultured on chocolate agar containing bacitracin rather than antiserum agar,"5 1 and that many patients had been given at least one dose of intravenous antibiotic treatment (usually chloramphenicol) before the swab was taken. The rapid decrease in the proportion of patients with swabs giving positive results reflects the ability of chloramphenicol, particularly, to suppress throat colonisation 2; this presumably reduces the risk of nosocomial transmission of H influenzae type b to a negligible level after the first day of treatment. The fact that most patients with disease other than meningitis or epiglottitis were treated with amoxycillin (which is less active than chloramphenicol in suppressing colonisation with H influenzae type b) probably explains the relatively high colonisation rate after several days of treatment.
Colonisation rates of 40% in child contacts not given rifampicin and 7% in adult contacts were lower than those reported in some other studies.7 11t2 In one study 71% of patients aged under 4 years and 44% of 5-10 year olds were colonised. The colonisation rate varies with household crowding.2 Some reports suggested that carrier rates are lower in contacts of patients with epiglottitis than in those of patients with meningitis (39% v 56% in one study and 14% v 27% in another), although the numbers of patients with epiglottitis were too small to show significance." In this study colonisation rates in the contacts of patients with epiglottitis did not differ significantly from those of patients with meningitis or other infections.
The use of rifampicin in contacts varied considerably. It was not clear whether this was owing to misinterpretation of the guidelines or use of alternative protocols. Rifampicin was prescribed least frequently, when indicated, in contacts of patients with infection other than meningitis and epiglottitis, presumably because the bacterial aetiology was not immediately obvious. It was more likely to be given when not indicated in contacts of patients with meningitis, which may reflect greater anxiety associated with this disease. The results confirm the ability of rifampicin, if given as recommended, to eradicate throat colonisation by H infiuenzae type b in most of those treated.5/721
However, the fact that the colonisation rate was relatively high at follow up among siblings who were given rifampicin but exposed to untreated household contacts emphasises the risk of colonisation. Previous studies showed that the use of rifampicin can protect contacts of patients with invasive H influenzae type b disease but, because of the fairly small proportion of cases which are attributable to secondary spread, its use has little impact on the overall incidence of the disease.6 There were no secondary cases (and only one coprimary case) among the patients in this study. In a previous study of 547 cases of invasive H influenzae type b disease in Victoria, three pairs of siblings, all aged under 5 years, were affected. Rifampicin pro-phylaxis had not been given to contacts of these patients, but only one of the "secondary" cases occurred within 30 days of the index case; the others were two months and three months apart. Although rifampicin prophylaxis is of limited value, the relatively poor compliance with the current recommendations suggests that its value is commonly reduced even further by incorrect use.
There has been concern that widespread use of rifampicin might lead to the development of rifampicin Of the 216 questionnaires distributed, 152 health districts replied (70%). Only 67 (45%) of these health districts had appointed a designated officer to oversee the screening process. Of the 150 replies, 95 named clinicians who had a special interest in congenital dislocation of the hip: 75 were orthopaedic surgeons, 13 were paediatricians, one was a community physician, and the others quoted a combination of specialties.
Comment
The revised memorandum on screening for congenital dislocation of the hip was widely circulated to professional groups and health authorities accompanied by a letter from the chief medical officer or chief nursing officer (C190(86)17, CNO(86)13). A press
